Figure 1.
Distribution of risk groups and mutation dynamics of 104 AML patients. (A) Distribution of 104 patients in each risk group defined by the revised ELN recommendations for AML. Thirty-one patients were favorable risk, 47 were intermediate risk, and 26 were adverse risk. (B) Bar plot shows mutational status of genes frequently detected at diagnosis. Color indicates sampling time point. Mutation status at diagnosis is colored red, pre-HCT blue, and post-HCT green. (C) Reduction of allelic burden of 256 mutations detected at diagnosis from initial diagnosis to pre-HCT is described. (D) Further clearance of persistent allelic burden from pre-HCT to post-HCT (day 21) is shown. (E) Summary of mutational status of 256 mutations from initial AML clones until 21 days after allogeneic HCT.

Distribution of risk groups and mutation dynamics of 104 AML patients. (A) Distribution of 104 patients in each risk group defined by the revised ELN recommendations for AML. Thirty-one patients were favorable risk, 47 were intermediate risk, and 26 were adverse risk. (B) Bar plot shows mutational status of genes frequently detected at diagnosis. Color indicates sampling time point. Mutation status at diagnosis is colored red, pre-HCT blue, and post-HCT green. (C) Reduction of allelic burden of 256 mutations detected at diagnosis from initial diagnosis to pre-HCT is described. (D) Further clearance of persistent allelic burden from pre-HCT to post-HCT (day 21) is shown. (E) Summary of mutational status of 256 mutations from initial AML clones until 21 days after allogeneic HCT.

Close Modal

or Create an Account

Close Modal
Close Modal